Why Celyad stock lost today instead of gaining on good news

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, Celyad announced that the first patient has received an injection in Phase 1 of the alloSHRINK clinical trial, evaluating its non-gene edited allogeneic CAR-T therapy known as CYAD-101. In this trial, FOLFOX chemotherapy is used simultaneously with CYAD-101 on patients with unresectable metastatic colorectal cancer (mCRC).

According to Dr. Christian Homsy, CEO of Celyad, CYAD-101 represents a potential first-in-class approach to allogeneic CAR . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.